Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.

The leading cause of end-stage renal disease (ESRD) is diabetic nephropathy. Interventions that prevent or palliate renal disease have a positive impact by improving patient care and diminishing healthcare costs. The following review summarizes clinical trals that evaluated treatment in various patient populations including Type 2 diabetic patients with microalbuminuria, subjects with proteinuric non-diabetic nephropathies, and Type 1 and Type 2 diabetic patients with overt nephropathy.

Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment.

The pharmacokinetics and pharmacodynamics of 7 days of treatment with losartan 50 mg/hydrochlorothiazide 12.5 mg were evaluated in 14 patients with normal renal function and in 12 patients with mild to moderate renal impairment. The efficacy of losartan 50 mg/hydrochlorothiazide 12.